On September 28, 2026, the US FDA approved Emcitate (tiratricol), the first treatment for MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. It is a once-daily liquid that lowers the excess thyroid hormone circulating in the body of children and adults living with this very rare genetic condition. For families who have waited years for any approved option, this is a genuine turning point, and there is an important detail many headlines skip: Europe approved it first.
Emcitate at a Glance: Quick Facts
- Drug: Emcitate (tiratricol), a thyroid hormone receptor agonist
- Condition: Peripheral thyrotoxicosis in MCT8 deficiency (Allan-Herndon-Dudley syndrome)
- Who it is for: Adults and pediatric patients. It is not recommended for primary hypothyroidism.
- How it is taken: Once daily as a liquid suspension, by mouth or through a feeding tube
- US approval: September 28, 2026 (Egetis Therapeutics US Inc.)
- EU approval: February 18, 2025, the first approved medicine for MCT8 deficiency in the EU
- Designations: Orphan Drug, Rare Pediatric Disease, Fast Track, Breakthrough Therapy and Priority Review
- US availability: Expected about eight to ten weeks after approval
What Is MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)?
MCT8 deficiency is a rare, inherited condition that mainly affects boys and men. It is X-linked and caused by changes in the SLC16A2 gene, which carries the instructions for building a protein called the MCT8 transporter. Think of that transporter as a doorway: its job is to carry thyroid hormone into cells, including brain cells.
Why the Brain and the Body Are Affected in Opposite Ways
When the doorway is broken, thyroid hormone cannot cross the blood-brain barrier properly. So the brain gets too little of it, while levels of the active hormone (T3) build up in the bloodstream and the rest of the body. That mismatch is what makes this disease so hard to treat, and so hard on families.
What Families and Doctors May Notice
- Inability to walk or sit independently
- Absent or very limited speech, and intellectual disability
- Feeding difficulties and poor weight gain
- A fast heart rate and high blood pressure from too much thyroid hormone in the body
- Muscle wasting, metabolic strain and a higher risk of infections
The company behind Emcitate reports a median life expectancy of around 35 years, which is why early diagnosis and coordinated specialist care matter so much.
How Does Emcitate Work?
Emcitate’s active ingredient, tiratricol, acts on thyroid hormone receptors. Here is the clever part: unlike natural thyroid hormone, it does not need the broken MCT8 transporter to get into cells.
Bypassing the Broken Transporter
FDA officials described it this way: the challenge was always that the protein needed to deliver thyroid hormone into cells is the one that is not working, and tiratricol sidesteps that problem. The result is a drop in the elevated thyroid hormone levels in the blood, which eases the strain on the heart and metabolism.
What Did the Clinical Studies Show?
The FDA reviewed two clinical studies in patients from infancy to adulthood: an international, multicenter, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. Across both:
- Patients on Emcitate had lower levels of excess thyroid hormone in the blood.
- They showed improvements in thyroid-driven cardiovascular and metabolic measures, such as systolic blood pressure and heart rate.
An Honest Note on What the Approval Covers
The approved use is to treat peripheral thyrotoxicosis, meaning the effects of excess thyroid hormone in the body. The FDA announcement does not describe an improvement in the neurological symptoms of the disease, so families should talk to their specialist about realistic goals.
The European approval was supported by Triac Trial I, a single-arm, open-label study in children and adults. In that trial, average blood T3 fell by more than 63% at month 12.
Emcitate Safety: What Patients and Doctors Should Know
Key Warnings
- Boxed warning: not for the treatment of obesity or for weight loss.
- Contraindication: primary hyperthyroidism.
- Thyrotoxicosis symptoms (fast heart rate, high blood pressure, diarrhea, sweating, irritability, insomnia) can occur when starting treatment or adjusting the dose, so the dose needs to be monitored and adjusted.
- Lab test interference: tiratricol can cross-react with T3 immunoassays and make T3 look higher than it really is, so results should be interpreted carefully.
- Other thyroid medicines: patients taking another thyroid medication should speak with their healthcare provider first, because the two should not be used together.
Most Common Side Effects
- Diarrhea
- Vomiting
- Rash
- Excessive sweating
Emcitate in the US vs Europe: What Is New for Patients
This is the part most news summaries leave out. The European Commission authorized Emcitate on February 18, 2025, for peripheral thyrotoxicosis in patients with MCT8 deficiency from birth. The US approval followed more than a year and a half later, on September 28, 2026.
- In the US: the manufacturer expects commercial supply about eight to ten weeks after approval and has launched a patient support program called Egetis RareLink, run with PANTHERx Rare.
- In the EU: it has been authorized since early 2025.
- Elsewhere: access depends on each country’s own regulator and on whether the product has been launched locally.
This is the third landmark rare-disease approval we have covered in recent weeks, after Zanvastro for Alexander disease and Isembyld for spinal muscular atrophy. You can follow more updates in our news section.
Access Outside the US: Where the Named Patient Program Fits
Newly approved rare-disease medicines often reach different countries at different times. If you are a patient, caregiver or physician outside the US or EU and need information about accessing a medicine like Emcitate, Indian Pharma Network can guide you through the Named Patient Program. Imports are made in the patient’s name on a valid prescription, under applicable regulations.
Frequently Asked Questions About Emcitate
What is Emcitate (tiratricol) used for?
Emcitate treats peripheral thyrotoxicosis, the effects of excess thyroid hormone in the body, in adults and children with MCT8 deficiency (Allan-Herndon-Dudley syndrome). It is not recommended for primary hypothyroidism.
Is Emcitate the first treatment for MCT8 deficiency?
Yes. It is the first FDA-approved therapy for the condition, and the European Commission had already authorized it in February 2025 as the first approved medicine for MCT8 deficiency in the EU.
How is Emcitate taken?
It is a once-daily liquid suspension taken by mouth or through a feeding tube, which makes it usable for patients who have difficulty swallowing. The dose is monitored and adjusted by the treating physician.
What are the side effects of Emcitate?
The most common are diarrhea, vomiting, rash and excessive sweating. It carries a boxed warning that it is not for obesity or weight loss, and it should not be used together with another thyroid medication.
When will Emcitate be available in the US?
The manufacturer expects it to be commercially available about eight to ten weeks after the September 28, 2026 approval.
Can patients in India get Emcitate?
Availability in India should be confirmed for each patient. Where a medicine is not marketed locally, it can be accessed through the Named Patient Program on a valid prescription. Contact Indian Pharma Network to discuss your case.
Last updated: October 6, 2026. This article is for general information and is not medical advice. Always consult a qualified specialist before making treatment decisions.
Sources: U.S. FDA press announcement, September 28, 2026; Egetis Therapeutics press release, September 28, 2026; European Commission approval announcement, February 2025.
